surpass cvot tirzepatide ACC 26: SURPASS-CVOT Long-awaited SURPASS-CVOT: Cardiovascular Outcomes with

SKU: 8673486464

Pay in 4 interest-free payments of $6.66 Learn more

Live Spec

Long awaited SURPASS CVOT: Cardiovascular Outcomes with Tirzepatide vs Dulaglutide in NEJM: #tirzepatide noninferior to #dulaglutide for 3 point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, and kidney function. Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP 1 Receptor Agonists? Highlights from SURPASS CVOT Diabetes Therapy Springer Nature Link Tirzepatide demonstrates cardiovascular protection in head to head trial with dulaglutide Efficacy and safety of a novel dual GIP and GLP 1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS 1): a double blind, randomised, phase 3 trial The Lancet SURPASS CVOT trial: For patients with high risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP 1 and glucose dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized

Store: capewinelands.gov.za · Domain: capewinelands.gov.za